Press Room

4th APV Continuous Manufacturing Conference

Start
Tuesday, May 09, 2023 - 09:00
End
Thursday, May 11, 2023 - 17:00
Location: Lisbon, Portugal
Hovione Lumiar Buildings R and S - aerial view

Hovione will be present and sponsor (gold sponsors) the 4th APV Continuous Manufacturing Conference from May 9-11. Don’t miss the chance to meet with our experts and learn more about the future of continuous manufacturing and how continuous tableting is right for your product. Hovione´s pragmatic approach to bridging science with manufacturing is now being leveraged for continuous tableting and it is the key to ultimately providing high quality medicines and the success of your drug product.

 

HOVIONE PRESENTATIONS

Tuesday, 09 May 2023 | Session 1: Manufacturing experience

A Roadmap to establish continuous tableting as a mainstream industrial platform
José Luís Santos - R&D Director - CoE Continuous Tableting

Tuesday, 09 May 2023 | Session 2: Process control

Control strategies for robust continuous manufacturing of oral dosage forms
Anthony Tantuccio - Fellow Scientist, Corporate Continuous Man. Project

Wednesday, 10 May 2023 | Session 4: Novel CM approaches

Enabling direct compression of amorphous solid dispersions
João Henriques - R&D Senior Manager, Formulation Development

 

The conference will be held in Lisbon - Portugal and includes a visit to our two sites: Hovione Lumiar and Hovione Loures.

 

Learn more about Continuous Tableting at Hovione

 

 

Also in the Press Room

See All

Hovione is bringing momentum to the intranasal field after announcing that its lead single-use nasal dry powder device, developed in collaboration with Industrial Design Consultancy Ltd (IDC), is now available for commercial partnerships. The milestone marks the transition from prototype to a fully integrated intranasal drug delivery platform that spans Hovione’s end-to-end partnership capabilities–from API synthesis through advanced formulation and particle engineering to drug product manufacturing, including device supply and advanced analytical tools for nasal performance characterization. The platform’s single-use device is designed to be manufacturable at scale and to leverage existing advanced particle engineering and drug product manufacturing capabilities, a practical advantage that can shorten timelines to clinic and commercialization while reducing development risk and cost. The device’s patented mechanism supports targeted nasal deposition, including access to the upper olfactory region. This enables rapid systemic absorption and potential nose-to-brain delivery pathways that are increasingly important for CNS and emergency-use indications. Beyond the single-use format, Hovione and IDC are advancing a multi-dose variant to broaden applicability across dosing regimens and therapeutic areas. The collaboration is backed by an intellectual property portfolio and initial patent grants, positioning the platform as a turnkey option for pharma partners seeking a single integrated supplier for both drug substance and device. This development arrives as intranasal delivery gains traction for systemic, CNS and rapid-onset therapies. This is precisely the focus of the upcoming 4th Nasal Formulation & Delivery Summit, for which Hovione is a key sponsor. The annual summit unites formulation, delivery and product development leaders to tackle drug-device compatibility, translational preclinical models, and strategies for scalable, regulatory-ready intranasal programs. Hovione’s recent progress will be highly relevant to attendees looking to de-risk nose-to-brain and systemic intranasal programs. Read the full article at News-Medical.net    

Press Clipping

Hovione advances intranasal drug delivery with commercial-ready dry powder platform ahead of 4th Nasal Formulation & Delivery Summit

Jun 01, 2026